(Q36976986)

English

Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial

scientific article published on 19 May 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

1 reference

14 September 2020

Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial (English)

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

phase III clinical trial

0 references

breast neoplasm

1 reference

14 September 2020

1 reference

24 July 2020

1 reference

14 September 2020

author name string

Mary E Peterson

1

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

publication date

19 May 2013

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

1 August 2013

6 references

13 March 2019

3 April 2019

17 June 2019

11 November 2019

24 July 2020

14 September 2020

Supportive Care in Cancer

7 references

Europe PubMed Central

PMC publication ID

17 August 2017

13 March 2019

3 April 2019

17 June 2019

11 November 2019

24 July 2020

14 September 2020

21

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

8

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

2341-2349

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

copyright license

Creative Commons Attribution-NonCommercial 2.0 Generic

19 May 2013

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

EASL clinical practice guidelines: Management of chronic hepatitis B virus infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699701

29 September 2017

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699701

29 September 2017

Managing stomatitis in patients treated with Mammalian target of rapamycin inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699701

29 September 2017

Therapeutic rationale for mTOR inhibition in advanced renal cell carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699701

29 September 2017

Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699701

29 September 2017

Ridaforolimus: a promising drug in the treatment of soft-tissue sarcoma and other malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699701

29 September 2017

Common toxicities of mammalian target of rapamycin inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699701

29 September 2017

Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699701

29 September 2017

Everolimus for advanced pancreatic neuroendocrine tumors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699701

29 September 2017

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699701

29 September 2017

New strategies in estrogen receptor-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699701

29 September 2017

Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699701

29 September 2017

Anemia management in oncology and hematology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699701

29 September 2017

Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699701

29 September 2017

The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699701

29 September 2017

Targeting the mTOR signaling network for cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699701

29 September 2017

Putting evidence into practice: evidence-based interventions for the management of oral mucositis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699701

29 September 2017

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699701

29 September 2017

The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699701

29 September 2017

p53 protein accumulation predicts resistance to endocrine therapy and decreased post-relapse survival in metastatic breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699701

29 September 2017

Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699701

29 September 2017

Cancer-related anemia and recombinant human erythropoietin--an updated overview

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699701

29 September 2017

Postmenopausal advanced breast cancer: options for therapy after tamoxifen and aromatase inhibitors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699701

29 September 2017

Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699701

29 September 2017

Nursing interventions and supportive care for the prevention and treatment of oral mucositis associated with cancer treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699701

29 September 2017

Mildly elevated liver transaminase levels in the asymptomatic patient.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699701

29 September 2017

Recommended guidelines for the treatment of cancer treatment-induced diarrhea

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699701

29 September 2017

Managing dyspnea and cough

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699701

29 September 2017

Management of chemotherapy-induced stomatitis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699701

29 September 2017

Management of dyspnea in advanced cancer patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699701

29 September 2017

Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699701

29 September 2017

The metabolic roles, pharmacology, and toxicology of lysine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699701

29 September 2017

Clinical and histopathologic characteristics of rash in cancer patients treated with mammalian target of rapamycin inhibitors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699701

4 September 2018

An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699701

4 September 2018

Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699701

4 September 2018

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699701

4 September 2018

Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699701

4 September 2018

Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. Update regarding the thiazolidinediones.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699701

4 September 2018

A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699701

4 September 2018

Management of cancer-related anemia in patients with breast or gynecologic cancer: new insights based on results from the European Cancer Anemia Survey

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699701

4 September 2018

Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3699701

4 September 2018

American Gastroenterological Association medical position statement: evaluation of liver chemistry tests

1 reference

https://pubmed.ncbi.nlm.nih.gov/23686401

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Supplemental Iron: A Key to Optimizing the Response of Cancer-Related Anemia to rHuEPO?

1 reference

https://pubmed.ncbi.nlm.nih.gov/23686401

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oral mucositis complicating chemotherapy and/or radiotherapy: options for prevention and treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/23686401

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00520-013-1826-3

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36976986&oldid=2199675820"